A new dementia drug which has the potential to slow down mental and function decline in Alzheimers patients has been given the sign off in the U.S by the FDA.
The drug, Aducanumab, is still in its early stages of proving its efficacy but it's approval in the US has been cautiously welcomed by Alzheimer's New Zealand.
Jesse speaks to Dr Phil Wood, a geriatric medicine specialist with an interest in Alzheimer's disease.
Photo: 123RF
